Page last updated: 2024-11-07

cicloprolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SL 75177-10: related to betaxolol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID146294
CHEMBL ID2110772
CHEBI ID135377
SCHEMBL ID634972
MeSH IDM0152063

Synonyms (32)

Synonym
gtpl552
cicloprolol
CHEBI:135377
L000657
1-[4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(propan-2-ylamino)propan-2-ol
2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-((1-methylethyl)amino)-
94651-09-9
63659-12-1
sl 75177-10
sl 75.177-10
91094-14-3
sl-75.177.10
sl 75-177-10
sl 75,177-10
1-(4-((2-cyclopropylmethoxy)ethoxy)phenoxy)-3-((1-methylethyl)amino)-2-propanol
1k2ach4u3r ,
sl 75117-10
(+-)-1-(p-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-(isopropylamino)-2-propanol
cicloprololum
unii-1k2ach4u3r
cicloprolol [inn:ban]
SCHEMBL634972
(+/-)-1-(p-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-(isopropylamino)-2-propanol
cicloprolol [inn]
2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-((1-methylethyl)amino)-, (+/-)-
cicloprolol [mart.]
CHEMBL2110772
sl 75.177-10 (9ci)
1-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-(propan-2-ylamino)propan-2-ol
Q15634018
DTXSID70867026
sl 75.177-10(9ci)

Research Excerpts

Overview

Cicloprolol is a partial beta 1-adrenoceptor agonist considered for the treatment of patients with coronary artery disease and impaired left ventricular function. Its haemodynamic and radionuclide (nuclear stethoscope) effects were determined in 22 patients.

ExcerptReferenceRelevance
"Cicloprolol is a new beta-blocking agent with high selectivity for beta 1 receptors and high intrinsic sympathomimetic activity. "( Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function.
Bonandi, L; Dei Cas, L; Ettori, F; Metra, M; Niccoli, L; Nodari, S; Visioli, O, 1992
)
1.93
"1. Cicloprolol is a partial beta 1-adrenoceptor agonist considered for the treatment of patients with coronary artery disease and impaired left ventricular function. "( Pharmacodynamic without pharmacokinetic interaction between cicloprolol, a partial beta 1-adrenoceptor agonist, and digoxin in healthy subjects.
Bianchetti, G; De Lauture, D; Dessault, O; Julien, J; Kahan, A; Morselli, PL; Pinquier, JL; Rosenzweig, P; Strauch, G; Weber, S, 1990
)
1.14
"Cicloprolol is a new cardioselective beta-blocking agent with partial agonist activity (intrinsic sympathomimetic activity, ISA). "( Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease.
Frais, MA; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1989
)
1.99
"Cicloprolol is a cardioselective beta-1 partial agonist; its haemodynamic and radionuclide (nuclear stethoscope) effects were determined in 22 patients with impaired left ventricular function due to coronary artery disease. "( Haemodynamic dose-response actions of cicloprolol in left ventricular dysfunction due to ischaemic heart disease.
Baig, W; Frais, MA; Jackson, NC; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1987
)
1.99

Effects

ExcerptReferenceRelevance
"Cicloprolol has significant partial agonist activity at the beta 1-adrenoceptor as indicated by increases in heart rate and systolic blood pressure."( Studies of the agonist and antagonist activity of cicloprolol in man.
Burke, M; McCaffrey, PM; Riddell, JG; Shanks, RG, 1988
)
1.25

Treatment

ExcerptReferenceRelevance
"Treatment with cicloprolol should protect the heart against excessive stimulation, while providing a baseline level of sympathetic drive."( An evaluation of the safety of the beta-modulator cicloprolol in chronic heart failure.
Alfiero, R; Cocco, G; Pouleur, H, 1992
)
0.88

Toxicity

ExcerptReferenceRelevance
" Thus, short-term administration of cicloprolol is safe in moderate heart failure."( An evaluation of the safety of the beta-modulator cicloprolol in chronic heart failure.
Alfiero, R; Cocco, G; Pouleur, H, 1992
)
0.81

Dosage Studied

ExcerptRelevanceReference
" Its haemodynamic profile was compared with that of atenolol (cardioselective; no ISA) in a comparative dose-response study of 24 ischaemic patients with diminished cardiac reserve."( Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease.
Frais, MA; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1989
)
0.55
" In order to mimic the intrinsic effects of the partial agonist drugs, control dose-response curves for isoproterenol were determined in pithed rats in which the base-line heart rate was elevated by thoracic spinal cord stimulation."( Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
Cavero, I; Hicks, PE; Langer, SZ; Lefevre-Borg, F; Manoury, P, 1987
)
0.49
"2 mg/kg dosage were assessed during supine bicycle exercise and compared with a control exercise period."( Haemodynamic dose-response actions of cicloprolol in left ventricular dysfunction due to ischaemic heart disease.
Baig, W; Frais, MA; Jackson, NC; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1987
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346250Human beta2-adrenoceptor (Adrenoceptors)1999European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1999European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (53.85)18.7374
1990's6 (46.15)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.29 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (37.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (62.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]